

-106-

What is claimed is:

1. An RNA compound between about 8 and 50 nucleobases in length targeted to human ICAM-1 mRNA, wherein said compound specifically hybridizes with said human ICAM-1 mRNA and inhibits the expression of human ICAM-1 mRNA.
2. The compound of claim 2 comprising between about 12 and 50 nucleobases in length.
3. The compound of claim 2 comprising between about 15 and 30 nucleobases in length.
4. The compound of claim 2, wherein said compound comprises SEQ ID NO: 22.
5. The compound of claim 2, wherein said compound is double stranded.
6. A double stranded RNA compound having SEQ ID NO:22
7. A method for treating airway hyperresponsiveness or pulmonary inflammation in an individual in need thereof, comprising administering to said individual an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding ICAM-1 protein to said individual.
8. The method of claim 7, wherein said antisense compound is an antisense oligonucleotide.
9. The method of claim 8, wherein at least one covalent linkage of said antisense compound is a modified covalent linkage.
10. The method of claim 8, wherein at least one nucleotide of said antisense compound has a modified sugar moiety.
11. The method of claim 8, wherein at least one nucleotide of

-107-

said antisense compound has a modified nucleobase.

12. The method of claim 8, further comprising administering an anti-asthma medication to said individual.
13. The method of claim 8 wherein said antisense compound comprises at least one lipophilic moiety which enhances the cellular uptake of said antisense compound.
14. The method of claim 8, wherein said antisense compound is aerosolized and inhaled by said individual.
15. The method of claim 8, wherein said antisense compound is administered intranasally, intrapulmonarily or intratracheally.
16. The method of claim 8, wherein said airway hyperresponsiveness or pulmonary inflammation is associated with asthma.
17. A pharmaceutical composition comprising an antisense oligonucleotide targeted to nucleic acid encoding ICAM-1 in a formulation suitable for intranasal, intrapulmonary or intratracheal administration.
18. The pharmaceutical composition of claim 17, wherein said composition is in a metered dose inhaler or nebulizer.